Whiterabbit.ai Announces Call for Radiologists to Participate in Study to Evaluate the Impact of Artificial Intelligence

First of its kind study tests the assumption that AI technology does not influence radiologists’ performance

Whiterabbit.ai, an AI company targeting late-stage diseases, announced efforts to recruit radiologists specializing in the field of mammography to participate in a two-session, retrospective study to evaluate the impact of artificial intelligence on radiologists’ performance. The study, developed in collaboration with researchers at the Stanford School of Medicine, will test the long-standing assumption made by the majority of peer-reviewed publications that the use of artificial intelligence does not influence radiologists’ performance.

AI and ML News: AI: Continuing the Chase for Brain-Level Efficiency

“This study comes at a pivotal time in the development of artificial intelligence-driven products, as innovative technology has the capability to significantly support radiologists’ workflow and inform decision making”

“This study comes at a pivotal time in the development of artificial intelligence-driven products, as innovative technology has the capability to significantly support radiologists’ workflow and inform decision making,” said Whiterabbit.ai CEO Alexander Sardiña, MD. “That could have important implications in clinical settings regarding the adoption of emerging AI technology, potentially overcoming detection and diagnostic challenges.”

Top Artificial Intelligence Insights: Could Instances of NLP Bias Derail AI?

The study, conducted at Stanford Medicine, will take place over two weekends in early 2023. Participating radiologists will read mammography cases without AI intervention and four to six weeks later will reread the cases with AI intervention.

Whiterabbit is an AI technology company with a mission to improve lives through earlier, more accurate cancer detection. A growing number of radiologists and healthcare providers are using Whiterabbit’s technology to improve patients’ experience with breast cancer screening. In addition to ACT, Whiterabbit has developed two other product lines – WRDensity and WRRisk. WRDensity is an FDA-cleared artificial intelligence-driven software that helps radiologists better assess breast density. WRRisk, a clinical decision support software based on well-established breast cancer risk models, assigns a risk rating to a patient and provides vital information to a physician to create a more personalized screening regimen with consistent follow-up and more accurate clinical diagnosis. Whiterabbit is headquartered in Santa Clara, California

AI ML in Marketing: AI and Big Data Analysis Used to Find Brands’ Emotional Connection

[To share your insights with us, please write to sghosh@martechseries.com]